Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia

BackgroundMethotrexate (MTX) is the primary drug used in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, some patients exhibit delayed clearance of high-dose (HD) MTX, which induces severe nephrotoxicity, mucositis, hepatotoxicity, and neurotoxicity. We sought to identify rel...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Jung Yoon Choi, Hoshik Kwon, Hyery Kim, Kyung Taek Hong, Youngeun Ma, Kyung-Nam Koh, Sunmin Yun, Keon Hee Yoo, Sang Hoon Song, Ho Joon Im, Ju Han Kim, Hyoung Jin Kang
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2024-11-01
סדרה:	Frontiers in Pharmacology
נושאים:	methotrexate children acute lymphoblastic leukemia pediatric pharmacogenomics adverse reactions
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1480657/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!